Boardroom Alpha
10-K primary document
DARE · Annual Report (Form 10-K) · Filed March 26, 2026

Dare Bioscience Inc10-K exhibit

dare-20251231xex231.htm
Document

Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
 
 
We consent to the incorporation by reference in the Registration Statement on Form S-1 (333-283280), the Registration Statements on Form S-3 (File Nos. 333-278380, 333-278378, 333-254862 and 333-238299) and the Registration Statements on Form S-8 (File Nos. 333-289607, 333-264020, 333-266699, 333-254864, 333-237473, 333-230802, 333-226904, 333-211697, 333-204007, and 333-198126) of Daré Bioscience, Inc. (the “Company”) of our report dated March 26, 2026, relating to the consolidated financial statements as of December 31, 2025 and 2024 and for each of the years in the two-year period then ended (which includes an explanatory paragraph expressing substantial doubt regarding the Company’s ability to continue as a going concern), which appear in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025.

 
/s/ Haskell & White LLP
HASKELL & WHITE LLP
 
Irvine, California
March 26, 2026


Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer